大缺血核心患者血管内取栓治疗综述
本文为叙述性综述,分析6项随机临床试验(RESCUE-Japan-LIMIT、ANGEL-ASPECT、SELECT2、TESLA、TENSION、LASTE)关于前循环大血管闭塞且ASPECTS≤5的缺血性卒中患者血管内取栓的疗效与安全性,其中5项达到主要疗效终点,1项接近达标;但晚时间窗、大核心体积及M2闭塞的疗效与安全性仍不确定。
要点
- 6项试验中5项达到主要疗效终点,1项接近达标,EVT对ASPECTS≤5患者总体结果呈阳性。
- 发病6小时内、前循环大血管闭塞且ASPECTS低的患者,EVT安全有效证据强。
- 超过6小时时间窗者EVT疗效与安全性仍不确定,现有数据不足以放弃先进影像评估。
核心结论
- 近期试验数据提供强证据表明,发病6小时内就诊的前循环大血管闭塞且ASPECTS低的卒中患者,EVT安全有效。
- 尽管接受EVT,患者结局仍常较差。
- 发病超过6小时的ASPECTS低患者,EVT疗效与安全性仍不确定,现有试验数据似乎过少,不足以支持在该延长时间窗内放弃先进卒中影像。
- 大核心体积(100 mL或以上)或M2闭塞(即大脑中动脉第二段闭塞)患者的EVT疗效与安全性仍不确定。
- 需要未来研究更好地识别可能对EVT有有意义应答的患者,以进一步优化卒中分诊流程和医疗资源利用。
研究设计与样本
- 本文为叙述性综述和对已发表试验的分析。
- 分析纳入6项随机临床试验:RESCUE-Japan-LIMIT、ANGEL-ASPECT、SELECT2、TESLA、TENSION和LASTE。
- 这些试验评估EVT治疗前循环大血管闭塞且ASPECTS≤5的缺血性卒中患者的疗效与安全性。
主要发现
- 6项试验中5项达到主要疗效终点,1项接近达标。
- 总体结果呈阳性。
- 对于发病6小时内就诊的前循环大血管闭塞且ASPECTS低的患者,EVT安全有效证据强。
- 发病超过6小时的ASPECTS低患者,EVT疗效与安全性仍不确定。
- 大核心体积(100 mL或以上)或M2闭塞患者的EVT疗效与安全性仍不确定。
关键数值与推荐
- 大缺血核心定义为ASPECTS≤5。
- 大核心体积定义为100 mL或以上。
- M2闭塞定义为大脑中动脉第二段闭塞。
临床怎么用
- 对于发病6小时内就诊的前循环大血管闭塞且ASPECTS≤5的卒中患者,近期试验数据提供强证据表明EVT安全有效。
- 对于发病超过6小时的ASPECTS低患者,现有试验数据似乎过少,不足以支持放弃先进卒中影像。
- 作者强调先进神经影像(如灌注和磁共振成像)在部分ASPECTS低患者EVT治疗决策中可能起重要作用。
- 原文未据此给出其他推荐。
局限性
- 发病超过6小时的ASPECTS低患者,EVT疗效与安全性仍不确定。
- 大核心体积(100 mL或以上)或M2闭塞患者的EVT疗效与安全性仍不确定。
- 尽管接受EVT,患者结局仍常较差。
- 现有试验数据似乎过少,不足以支持在延长时间窗内放弃先进卒中影像。
- 需要未来研究更好地识别可能对EVT有有意义应答的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recently, 6 randomized clinical trials-RESCUE-Japan-LIMIT (Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Large Ischemic Core Trial), ANGEL-ASPECT (Trial of Endovascular Therapy for Acute Ischemic Stroke With Large Infarct), SELECT2 (Trial of Endovascular Thrombectomy for Large Ischemic Strokes), TESLA (Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke), TENSION (Endovascular Thrombectomy for Acute Ischemic Stroke With Established Large Infarct), and LASTE (Large Stroke Therapy Evaluation)-have concluded their investigations on the efficacy and safety of endovascular thrombectomy (EVT) for the treatment of patients with ischemic stroke, anterior-circulation large vessel occlusions, and large areas of ischemic changes defined as an Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 5 or less. Overall, the results appeared to be positive, with 5 of the 6 trials meeting their primary efficacy end point, and 1 trial that was a near miss. However, questions remain regarding how these trial results should be interpreted and incorporated into routine clinical practice. OBSERVATIONS: In this narrative review and analysis of published trials, important nuances of the available clinical data were identified, and important areas of lingering uncertainty were highlighted, including the efficacy and safety of EVT for patients with a low ASPECTS score in late treatment windows and those with large core volumes. Also emphasized was the possibly important role of advanced neuroimaging modalities such as perfusion and magnetic resonance imaging when making EVT treatment decisions for select patients with low ASPECTS scores. CONCLUSIONS AND RELEVANCE: Recent trial data provide strong evidence that EVT is safe and effective for patients with anterior, large vessel-occlusion stroke and low ASPECTS scores who present within 6 hours from stroke onset. However, patient outcomes often remain poor despite EVT treatment. The efficacy and safety of EVT for patients with low ASPECTS scores who present beyond 6 hours of stroke onset remain uncertain, and the current trial data seem too scarce to justify forgoing advanced stroke imaging during this extended time window. Furthermore, the efficacy and safety of EVT for patients with large core volumes (100 mL or greater) or M2 occlusions (ie, occlusions of the second segment of the middle cerebral artery) remain uncertain. Future research to better identify patients likely to meaningfully respond to EVT is needed to further optimize the stroke triage process and health care resource utilization.
引用
- Chen H, Lee JS, Michel P, et al. Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core: A Review. JAMA Neurol. 2024. PMID: 39133467. doi:10.1001/jamaneurol.2024.2500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。